Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 5

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 2025 AND 2024

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Three months ended   March 31,   2025  2024 Cash flows from operating activities:      Net loss $(623,327) $(103,757)         Adjustments to reconcile net loss to net cash used in operating activities:        Amortization of right-of-use asset  13,379   9,448 Allowances for expected credit losses  40,124   120,469 Recoveries for expected credit losses  (25,153)  (31,752)Depreciation of property, plant and equipment  26,642   20,138 Dividend income  (8,934)  (8,946)Fair value loss/(gain) on investments in equity securities  63,983   (40,488)Gain on disposal of investments in equity securities  -   (6,181)Operating loss before working capital changes  (513,286)  (41,069)         Changes in operating assets and liabilities:        Inventories  209,480   60,817 Trade and other receivables  (112,615)  (112,473)Trade and other payables  (317,522)  55,227 Advance payment from customer  (73,915)  5,578 Operating lease liabilities  (10,444)  (12,041)Tax (liabilities)/recoverable  (5,770)  6,808 Net cash used in operating activities  (824,072)  (37,153)         Cash flows from investing activities:        Acquisition of investments in equity securities  -   (174,247)Dividend income  8,934   8,946 Change in fixed deposits placed with original maturities more than three months  (15,528)  (20,448)Purchase of plant and equipment  (9,052)  (21,945)Proceeds from disposal of investment in equity securities  -   211,344 Net cash (used in)/generated from investing activities  (15,646)  3,650          Cash